Atomic Therapeutic Indicator for Tumor Radio-Responsiveness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment decisions regarding radiation therapy lack quantitative indicators, relying heavily on subjective pathological analysis, leading to overtreatment and undertreatment due to the inability to objectively assess tumor radio-sensitivity and radio-resistance.
Innovation Solution
The method involves quantifying manganese levels in 3D regions of a test sample using a 2D coordinate system, calculating the central tendency of manganese levels in voxels to generate an Atomic Therapeutic Indicator (ATI), which determines radio-responsiveness, and identifying high metallomic regions to predict cancer recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If quantitative manganese quantification in 3D voxels is implemented, then measurement precision of radio-responsiveness is improved, but device complexity and measurement methodology complexity increase
Solution Approach 1:
The patent replaces traditional mechanical/pathological assessment methods with atomic-level quantification using mass spectrometry. By substituting subjective pathological examination with objective atomic concentration measurement (manganese levels in voxels), the system achieves precise radio-responsiveness assessment while the automated analysis software handles the complexity of 3D data processing.
Solution Approach 2:
The invention changes the measurement parameter from macroscopic tissue morphology to atomic concentration (manganese levels). By quantifying manganese concentration in 3D voxels and calculating central tendency values, the system transforms complex biological responses into a single measurable parameter (ATI) that directly indicates radio-responsiveness.
2Ease of operation
If subjective pathological analysis is used, then ease of operation is maintained, but measurement precision and reliability of treatment decisions deteriorate
Solution Approach 1:
The system enables self-service by allowing the tissue sample to provide its own diagnostic information through atomic composition. The manganese distribution pattern within the tumor tissue inherently encodes radio-responsiveness information, eliminating the need for complex expert interpretation while maintaining operational simplicity through automated analysis.
3Productivity
If radiation treatment is administered based on current methods, then productivity of cancer treatment is maintained, but loss of information regarding individual tumor characteristics increases leading to overtreatment and undertreatment
Solution Approach 1:
The patent performs preliminary quantification of manganese levels and generation of ATI values before treatment decisions are made. By establishing the radio-responsiveness profile in advance through atomic analysis, the system prevents information loss and enables optimized treatment planning that avoids both overtreatment and undertreatment while maintaining efficient treatment delivery.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to the generation of an Atomic Therapeutic Indicator (ATI) for a test sample by the quantification of manganese; in voxels of a 3D region of the sample, wherein the 3D region is topographically defined by co-ordinates X'xY'xZ. The ATI is used to assess the radio-responsiveness i.e. sensitivity or resistance to radiation treatment, of a cancer i.e. a tumour/neoplasm. In a preferred embodiment, the present invention relates to a method of generating the ATI, assessing the radio- responsiveness of a tumour/neoplasm based on the ATI and, based on the assessment, either treating or not treating the tumour with radiation. The present invention also relates to a method of determining if a cancer is likely to reoccur post radiation treatment comprising quantifying the level of manganese in voxels of a 3D region of a test sample from the cancer and determining the frequency of high metallomic regions (HMRs) in the cancer, wherein a high frequency of HMRs is indicative that the cancer is likely to reoccur and a low frequency of HMRs is indicative that the cancer is unlikely to reoccur; and associated methods of treatment.